An evaluation of the safety and tolerability of different doses of (open study section) HLX02 in Chinese healthy male subjects compared HLX02 and Herceptin (in USA and Germany) the pharmacokinetics, safety phase I clinical study, tolerability and immunogenicity: randomized, double-blind, parallel-group portion

Trial Profile

An evaluation of the safety and tolerability of different doses of (open study section) HLX02 in Chinese healthy male subjects compared HLX02 and Herceptin (in USA and Germany) the pharmacokinetics, safety phase I clinical study, tolerability and immunogenicity: randomized, double-blind, parallel-group portion

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2016

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top